RFA-AG-23-010: Noncoding RNAs in Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 15, 2022.
From the official notice on Grants.gov, last changed February 28, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIA
- Median yearly award$659,427
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-AG-23-010 were run by National Institute on Aging (NIA, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AG-23-010 in the NIH Guide.
Key dates
| Posted | February 28, 2022 |
|---|---|
| Deadline | July 15, 2022 |
| Archived by Grants.gov | August 20, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research in noncoding ribonucleic acids (ncRNAs) to investigate the causality, directionality, mechanisms, and therapeutic potential of ncRNAs in Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). This FOA will support applications seeking to discover novel mechanisms mediated by ncRNAs, elucidate molecular, and cellular functions involved in the pathogenesis and progression of AD/ADRD.
Funded under RFA-AG-23-010 so far
NIH funded 7 projects under RFA-AG-23-010 in fiscal 2023 to 2026, at 7 institutions. The median yearly award was $659,427.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | University of Kentucky | 2026 | $651,889 |
| The role of IncRNA Neat1 in Alzheimer's disease and related memory deficits | University of Alabama at Birmingham | 2026 | $657,110 |
| Sex-specific regulation of microRNAs in Alzheimer Disease | Loyola University Chicago | 2026 | $653,367 |
| miR-29: A brain homeostasis molecule for Alzheimer’s disease prevention | Univ of North Carolina Chapel Hill | 2026 | $633,496 |
| Enhancer RNAs in brain gene regulation and Alzheimer's disease | University of Texas HLTH Sci Ctr Houston | 2026 | $734,228 |
| Non-coding RNAs in resilience to Alzheimer’s Disease | Beth Israel Deaconess Medical Center | 2026 | $844,278 |
| Targeting specific MicroRNA to alleviate Alzheimer’s Disease pathobiology | Ohio State University | 2026 | $685,448 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AG-23-010 still open?
No. It closed on July 15, 2022.
Who can apply for Noncoding RNAs in Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Noncoding RNAs in Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)?
Closed July 15, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-AG-23-010?
NIH RePORTER lists 7 projects funded under RFA-AG-23-010 in fiscal 2023 to 2026, at 7 institutions. The most were at University of Kentucky, University of Alabama at Birmingham, Loyola University Chicago.
Who has won Aging Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, The Trustees of Columbia University in the City of New York, University of Southern California. The program made 11,026 awards worth $19 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)